Spiga, Francesca and Parkhouse, Thomas and Tang, Victor M and Savović, Jelena and Le Foll, Bernard and Nielsen, Suzanne (2025) Pharmacotherapies for cannabis use disorder. Cochrane Database of Systematic Reviews, (9), Art no. CD008940. DOI: 10.1002/14651858.CD008940.pub4.
External website: https://www.cochranelibrary.com/cdsr/doi/10.1002/1...
Conclusions: There is incomplete evidence for all the clinically‐important pharmacotherapies investigated and, for half of their outcomes, the quality of the evidence was low (44%) or very low (11%). Given the limited evidence of efficacy, those pharmacotherapies should still be considered experimental for treating cannabis use disorder. The greater withdrawal from treatment due to adverse effects seen with anticonvulsants and mood stabilisers may limit their therapeutic value.
B Substances > New (novel) psychoactive substances > Other novel substances > Gabapentinoids GABA (Pregabalin / Gabapentin)
G Health and disease > Substance use disorder (addiction) > Drug use disorder > Drug withdrawal / craving
G Health and disease > Substance related disorder > Substance related mental health disorder > Dual diagnosis / comorbidity (mental health)
HJ Treatment or recovery method > Substance disorder treatment method > Substance disorder drug therapy (pharmacological treatment)
HJ Treatment or recovery method > Treatment outcome
J Health care, prevention, harm reduction and treatment > Treatment and maintenance > Treatment factors
VA Geographic area > International
Repository Staff Only: item control page